Login
- Titel:
Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms.
- Dokumenttyp:
- Journal Article; Article
- Autor(en):
- Schneider, Katharina Luise; Kunst, Melanie; Leuchs, Ann-Kristin; Böhme, Miriam; Weckbecker, Klaus; Kastenmüller, Kathrin; Bleckwenn, Markus; Holdenrieder, Stefan; Coch, Christoph; Hartmann, Gunther; Stingl, Julia Carolin
- Abstract:
- BACKGROUND: Dose requirements of vitamin K antagonists are associated with CYP2C9 and VKORC1, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear. METHODS: Aim was to scrutinize phenprocoumon dose requirements, dose stability and anticoagulation quality in association to CYP2C9 and VKORC1 in a natural cohort of elderly primary care patients. As a subgroup within the IDrug study, phenprocoumon treated patients with at least two INR values within three months before enrollment (n = 209) were analyzed concerning average weekly dose, standard deviation of weekly dose (intra-subject variability), constant dose (yes/no), average INR and TTR grouped by CYP2C9 and VKORC1 (and combinations). RESULTS: Average weekly dose per patient was 14.4 ± 5.3 mg, 11.9 ± 4.0 mg and 11.2 ± 4.3 mg in CYP2C9 wildtypes, *2 and *3 carriers (p < .0001) and 16.0 ± 4.2 mg, 13.3 ± 5.1 mg and 8.0 ± 2.7 mg per week in VKORC1 CC, CT and TT genotypes, respectively (p < .0001). Significant differences concerning intra-subject variability were detected among all groups (p < .0001) with the smallest variability in CYP2C9*3 carriers. TTR medians were 75.4%, 79.4% and 100% in wildtypes, *2 and *3 carriers, respectively (p = 0.0464). The proportion of patients with perfect control was highest among *3 carriers, but this result was not significant (p = 0.0713). DISCUSSION: Our analyses support the results of previous investigations regarding genotype-associated dose requirements and raise the hypothesis that dose stability and anticoagulation quality may be increased in CYP2C9*3 carriers. However, our data should be treated cautiously due to the small sample size. CLINICAL TRIAL REGISTRATION: German Clinical Trials Register, identifier DRKS00006256.
- Zeitschriftentitel:
- Front Pharmacol
- Jahr:
- 2020
- Band / Volume:
- 10
- Volltext / DOI:
- doi:10.3389/fphar.2019.01620
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/32047440
- TUM Einrichtung:
- Institut für Laboratoriumsmedizin (keine SAP-Zuordnung!)
BibTeX